Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

Name: Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
License: Public Domain

AIO-Studien-gGmbH

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

metastatic renal cell carcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 148760
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.